Corbus Pharmaceuticals (CRBP) Upgraded to “Hold” at BidaskClub
Corbus Pharmaceuticals (NASDAQ:CRBP) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a report released on Friday.
CRBP has been the topic of several other reports. Cantor Fitzgerald set a $28.00 price objective on shares of Corbus Pharmaceuticals and gave the company an “overweight” rating in a report on Thursday, December 14th. Noble Financial restated a “buy” rating on shares of Corbus Pharmaceuticals in a research note on Saturday, December 23rd. Finally, ValuEngine downgraded shares of Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, September 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $25.00.
Corbus Pharmaceuticals (CRBP) opened at $7.35 on Friday. Corbus Pharmaceuticals has a fifty-two week low of $5.30 and a fifty-two week high of $10.50. The company has a market cap of $397.83, a price-to-earnings ratio of -11.67 and a beta of 2.30.
Corbus Pharmaceuticals (NASDAQ:CRBP) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.02. Corbus Pharmaceuticals had a negative net margin of 1,040.41% and a negative return on equity of 96.02%. The firm had revenue of $0.80 million for the quarter. equities research analysts expect that Corbus Pharmaceuticals will post -0.6 EPS for the current fiscal year.
In other Corbus Pharmaceuticals news, Director David P. Hochman purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The shares were acquired at an average cost of $7.08 per share, for a total transaction of $70,800.00. Following the completion of the purchase, the director now owns 459,500 shares of the company’s stock, valued at approximately $3,253,260. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director David P. Hochman purchased 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The stock was acquired at an average price of $6.55 per share, for a total transaction of $32,750.00. Following the completion of the purchase, the director now directly owns 459,500 shares of the company’s stock, valued at approximately $3,009,725. The disclosure for this purchase can be found here. Insiders purchased 25,336 shares of company stock worth $175,632 over the last 90 days. 11.90% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. State Board of Administration of Florida Retirement System bought a new stake in Corbus Pharmaceuticals during the third quarter worth about $108,000. Yellowstone Partners LLC bought a new stake in Corbus Pharmaceuticals during the third quarter worth about $110,000. Credit Suisse AG bought a new stake in Corbus Pharmaceuticals during the first quarter worth about $157,000. Voya Investment Management LLC bought a new stake in Corbus Pharmaceuticals during the second quarter worth about $125,000. Finally, Capital Fund Management S.A. bought a new stake in Corbus Pharmaceuticals during the second quarter worth about $130,000. 27.84% of the stock is owned by institutional investors and hedge funds.
Corbus Pharmaceuticals Company Profile
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.